血清前列腺特异性抗原对良性前列腺增生患者前列腺体积的预测价值

周浩; 孙超; 李博; 关翰; 陈志军

doi:10.16766/j.cnki.issn.1674-4152.001726

血清前列腺特异性抗原对良性前列腺增生患者前列腺体积的预测价值

doi: 10.16766/j.cnki.issn.1674-4152.001726

周浩¹,
孙超¹,
李博¹,
关翰²,
陈志军^2, ,

1.
蚌埠市第三人民医院泌尿外科，安徽蚌埠 233000
2.
蚌埠医学院第一附属医院泌尿外科，安徽蚌埠 233004

基金项目:

安徽省教育厅重点项目 KJ2019A0355

详细信息

通讯作者:
陈志军，E-mail：bb_czj@126.com

中图分类号: R697.3 R446
计量
- 文章访问数: 161
- HTML全文浏览量: 64
- PDF下载量: 1
- 被引次数: 0
出版历程
- 收稿日期: 2020-07-15
- 网络出版日期: 2022-02-19

The predictive value of serum prostate-specific antigen on prostate volume in patients with benign prostatic hyperplasia

ZHOU Hao¹,
SUN Chao¹,
LI Bo¹,
GUAN Han²,
CHEN Zhi-jun^{2
, ,}

1.
Department of Urology, the Third People's Hospital of Bengbu City, Bengbu, Anhui 233000, China

摘要

摘要: 目的通过分析血清总前列腺特异性抗原(total prostate specific antigen，tPSA)、游离前列腺特异性抗原(free prostate specific antigen，fPSA)、年龄与前列腺体积(prostate volume，PV)之间的关系，评估其预测前列腺体积的价值。方法整理2018年1月—2019年12月期间蚌埠市第三人民医院泌尿外科收治的111例前列腺增生患者的临床资料，所有患者均行前列腺电切术且病理证实为良性腺体增生。采用方差分析、LSD多重比较法分析不同年龄段的前列腺体积、tPSA、fPSA及不同前列腺体积的血清tPSA、fPSA的差异，进一步应用Pearson相关性分析描述患者年龄、tPSA、fPSA与PV之间的相关性，用于评估年龄、tPSA、fPSA预测PV的价值。结果 3个年龄段之间的前列腺体积、tPSA、fPSA差异具有统计学意义(F=5.137, P=0.007；F=7.551, P=0.001；F=5.186, P=0.007)，3个年龄段间两两比较后发现60~69岁组与70~79岁组和≥80岁组前列腺体积、tPSA、fPSA比较差异有统计学意义，但不同前列腺体积患者血清tPSA、fPSA值差异存在统计学意义(F=8.187，P < 0.001；F=7.318，P=0.001)，血清tPSA、fPSA值随前列腺体积增加而升高(均P < 0.05)。患者的年龄、血清tPSA及血fPSA与PV呈正相关(r=0.259, P=0.006；r=0.375, P < 0.001；r=0.339，P < 0.001)。结论可以通过检测血清中的tPSA、fPSA水平预测PV, 有利于判断良性前列腺增生(BPH)患者的病情发展程度、评估手术风险以及预后随访。
- 前列腺增生 /
- 前列腺特异性抗原 /
- 前列腺体积
Abstract: Objective To evaluate the value of predicting prostate volume by analyzing the relationship between serum total prostate specific antigen (tPSA), free prostate specific antigen (fPSA), age and prostate volume (PV). Methods The clinical data of 111 patients with benign prostatic hyperplasia admitted to the Department of Urology, Bengbu Third People's Hospital from January 2018 to December 2019 were compiled. All patients underwent prostatectomy and pathologically confirmed benign glandular hyperplasia. Variance analysis and LSD multiple comparison method were used to analyze the differences in prostate volume, tPSA, fPSA of different age groups, and the differences in serum tPSA and fPSA of different prostate volumes. Pearson correlation analysis was further used to describe the difference between patient age, tPSA, fPSA and PV, and evaluate the value of age, tPSA, and fPSA in predicting PV. Results The differences in prostate volume, tPSA, and fPSA among the three age groups were statistically significant (F=5.137, P=0.007; F=7.551, P=0.001; F=5.186, P=0.007). After pairwise comparison, it was found that prostate volume, tPSA, and fPSA were not completely statistically significant, but there were statistical differences in serum tPSA and fPSA values of prostate volumes of different sizes (F= 8.187, P < 0.001; F=7.318, P=0.001), the serum tPSA and fPSA values increased with the increase of the anterior gland volume (all P < 0.05). The patient's age, serum tPSA and blood fPSA were positively correlated with PV (r=0.259, P=0.006; r=0.375, P < 0.001; r=0.339, P < 0.001). Conclusion The detection of serum tPSA and fPSA levels can be used to predict PV, which is helpful for judging the degree of disease development of patients with benign prostatic hyperplasia (BPH), assessing surgical risk and prognostic follow-up.
- Prostatic hyperplasia /
- Prostate specific antigen /
- Prostate volume

HTML全文

表 1 不同年龄段前列腺增生患者血清tPSA、fPSA及前列腺体积比较(x±s)

组别	例数	前列腺体积 (mL)	tPSA (ng/mL)	fPSA (ng/mL)
60~69岁	36	51.16±24.60	3.85±2.62	0.78±0.54
70~79岁	59	71.84±35.17^a	7.62±5.38^a	1.25±0.84^a
≥80岁	16	70.68±30.56^a	7.25±5.55^a	1.24±0.59^a
F值		5.137	7.551	5.168
P值		0.007	0.001	0.007
注：与60~69岁组比较，^aP < 0.05。

下载: 导出CSV

表 2 不同前列腺体积前列腺增生患者血清tPSA、fPSA比较(x±s，ng/mL)

组别	例数	tPSA	fPSA
≤40 mL	27	3.65±2.94	0.67±0.55
40~80 mL	50	6.33±4.53^a	1.15±0.70^a
≥80 mL	34	8.52±5.84^ab	1.35±0.82^ab
F值		8.187	7.318
P值		< 0.001	0.001
注：与≤40 mL组比较，^aP < 0.05；与40~80 mL组比较，^bP < 0.05。

下载: 导出CSV

参考文献(21)

[1]	王倩, 杨胜楠, 赵倩茹, 等. 高龄男性患者前列腺增生与肾功能的相关性研究[J]. 中华老年医学杂志, 2018, 37(3): 284-287.
[2]	李荣均, 伍建锋, 刘映云, 等. 代谢综合征对老年前列腺增生患者临床病程进展各指标的影响[J]. 中国男科学杂志, 2016, 30(11): 16-19. https://www.cnki.com.cn/Article/CJFDTOTAL-NXXX201611003.htm
[3]	RENDON R A, MASON R J, MARZOUK K, et al. Canadian Urological Association recommendations on prostate cancer screening and early diagnosis[J]. Can Urol Assoc J, 2017, 11(10): 298-309. doi: 10.5489/cuaj.4888
[4]	杨刚华, 张剑琴, 马茂, 等. 代谢综合征相关指标对老年人前列腺的影响[J]. 中国现代医学杂志, 2020, 30(1): 93-97. https://www.cnki.com.cn/Article/CJFDTOTAL-ZXDY202001017.htm
[5]	BANSAL A, ARORA A. Predictors of successful trial without catheter following acute urinary retention in benign prostatic enlargement: A single centre, multivariate analysis[J]. Neurourol Urodyn, 2017, 36(7): 1757-1762. doi: 10.1002/nau.23194
[6]	YOSHIDA T, KINOSHITA H, YOSHIDA K, et al. Intravesical prostatic protrusion as a predicting factor for the adverse clinical outcome in patients with symptomatic benign prostatic enlargement treated with dutasteride[J]. Urology, 2016, 91(1): 154-157. http://www.sciencedirect.com/science/article/pii/S0090429516000625
[7]	CHOI B R, KIM H K, SONI K K, et al. Additive effect of oral LDD175 to tamsulosin and finasteride in a benign prostate hyper-plasia rat model[J]. Drug Des Devel Ther, 2018, 12(9): 1855-1863. http://www.dovepress.com/getfile.php?fileID=42761
[8]	伊庆同, 龚旻, 胡巍, 等. 上海浦东新区良性前列腺增生合并膀胱过度活动症的流行病学调查[J]. 现代泌尿外科杂志, 2017, 22(10): 732-737. https://www.cnki.com.cn/Article/CJFDTOTAL-MNWK201710003.htm
[9]	陈昊, 吴晓鸣. 血清炎症因子、转化生长因子-1、前列腺特异抗原及前列腺特异抗原密度在老年前列腺增生患者中的表达及意义[J]. 中国老年学杂志, 2018, 38(4): 860-861. https://www.cnki.com.cn/Article/CJFDTOTAL-ZLXZ201804041.htm
[10]	李树平, 贺凯, 阳大庆, 等. 尿肌氨酸与血清PSA在前列腺癌早期诊断中的意义[J]. 中国男科学杂志, 2017, 31(2): 33-35. https://www.cnki.com.cn/Article/CJFDTOTAL-NXXX201702007.htm
[11]	张舒娴, 王泽洲, 施榕, 等. 社区非前列腺癌男性人群血清前列腺特异性抗原影响因素研究[J]. 中华全科医学, 2019, 17(2): 252-255. https://www.cnki.com.cn/Article/CJFDTOTAL-SYQY201902025.htm
[12]	黄考平, 温世和, 杨天. 血清PSA与良性前列腺增生临床病理的相关性研究[J]. 中国实用医药, 2019, 14(34): 66-67. https://www.cnki.com.cn/Article/CJFDTOTAL-ZSSA201934031.htm
[13]	刘克玉. 超声测量前列腺体积与年龄、PSA、PSAD的相关性研究[J]. 影像研究与医学应用, 2018, 2(21): 108-109. https://www.cnki.com.cn/Article/CJFDTOTAL-YXYY201821067.htm
[14]	张晓波. 前列腺增生症患者PSA、PSAD与年龄、前列腺体积相互关系的临床研究[J]. 实用中西医结合临床, 2016, 16(2): 35-36. https://www.cnki.com.cn/Article/CJFDTOTAL-SZXL201602016.htm
[15]	徐良, 吴宁, 蔡启亮, 等. BPH患者年龄、睾酮水平、体重指数、前列腺体积及血清前列腺特异性抗原的关系分析[J]. 临床泌尿外科杂志, 2016, 31(6): 508-512. https://www.cnki.com.cn/Article/CJFDTOTAL-LCMW201606006.htm
[16]	刘起. 睾酮水平、BMI、PSA水平变化与BPH发病相关性分析及作用机制分析[J]. 黑龙江医学, 2019, 43(12): 1446-1447, 1451. https://www.cnki.com.cn/Article/CJFDTOTAL-HLYX201912007.htm
[17]	COBAN S, DOLUOGLU O G, KELES I, et al. Age and total and free prostate-specific antigen levels for predicting prostate volume in patients with benign prostatic hyperplasia[J]. Aging Male, 2016, 19(2): 124-127. doi: 10.3109/13685538.2015.1131260
[18]	杨文俊, 胡成, 刘思容, 等. 血清前列腺特异性抗原预测中国男性前列腺增生患者前列腺体积的准确性研究[J]. 中华腔镜泌尿外科杂志(电子版), 2018, 12(3): 154-158. https://www.cnki.com.cn/Article/CJFDTOTAL-ZHQJ201803003.htm
[19]	蒋团建, 黄仁胜. 血清PSA水平在良性前列腺增生患者术后预后判断中的价值[J]. 中国民康医学, 2019, 31(10): 124-126. https://www.cnki.com.cn/Article/CJFDTOTAL-ZMYX201910056.htm
[20]	NUNZIO C D, AUTORINO R, BACHMANN A, et al. The diagnosis of benign prostatic obstruction: Development of a clinical nomogram[J]. Neurourol Urodyn, 2016, 35(2): 235-240. doi: 10.1002/nau.22705
[21]	CORIC J, MUJIC J, KUCUKALIC E, et al. Prostate-specific antigen(PSA) and prostate volume: better predictor of prostate cancer for bosnian and Herzegovina men[J]. Open Biochem J, 2015, 15(9): 34-36. doi: 10.2174/1874091x01509010034